Skip to main content
Neural Therapeutics Inc. logo

Neural Therapeutics Inc. — Investor Relations & Filings

Ticker · NURL ISIN · CA64134N2032 LEI · 894500KBZO3KS9715774 CSE Manufacturing
Open in API
Filings indexed 141 across all filing types
Latest filing 2023-06-13 Capital/Financing Update
Country CA Canada
Listing CSE NURL

About Neural Therapeutics Inc.

https://neuraltherapeutics.ca/

Neural Therapeutics Inc. is an ethnobotanical drug discovery and development company operating in the pharmaceutical and nutraceutical sectors. It focuses on developing therapeutic drugs for mental illnesses, including those related to substance abuse, and over-the-counter dietary supplements. The company integrates modern scientific research with traditional indigenous knowledge regarding psychoactive plants and whole plant extracts. Initial R&D centers on the San Pedro cactus (Echinopsis pachanoi), which contains mescaline. Neural Therapeutics pursues a dual-path strategy to develop both pharmaceutical and nutraceutical products, aiming for whole plant utilization and zero waste.

Recent filings

Filing Released Lang Actions
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed notice to shareholders about a rights offering by Neural Therapeutics Inc. It includes information on eligibility, subscription rights, pricing, and procedures for exercising rights. The content focuses on a capital raising event through issuing rights to existing shareholders. There are no financial statements or earnings data, nor is it a report or announcement of voting results or management changes. The document is not a regulatory filing or certification but a direct communication about a financing activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (7085 characters) supports it being a full notice rather than a brief announcement or regulatory filing.
2023-06-13 English
Other.pdf
Capital/Financing Update Classification · 100% confidence The document is titled 'Avis de Placement de Droits' (Notice of Rights Offering) and details a rights offering by Neural Therapeutics Inc. It discusses the issuance of rights to shareholders to subscribe for additional shares, the subscription price, eligibility, and procedures for exercising the rights. The document is an announcement informing shareholders about a capital raising event through a rights offering. It does not contain financial statements or detailed financial analysis but rather provides information about the capital raising process and subscription terms. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2023-06-13 English
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a rights offering and a concurrent private placement by Neural Therapeutics Inc. It details the terms of the rights offering, subscription price, record date, expiry date, and the concurrent private placement including the number of shares and pricing. The document also includes forward-looking statements and disclaimers typical of capital raising announcements. There are no financial statements, audit information, or detailed financial analysis present. The document is not a report but an announcement of financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the financing event, supporting a high confidence in classification.
2023-06-13 English
Other.pdf
Capital/Financing Update Classification · 100% confidence The document is titled 'Rights Offering Circular' and contains detailed information about a rights offering by Neural Therapeutics Inc., including subscription prices, eligibility, use of funds, and legal disclaimers. It is a comprehensive circular prepared by management to inform shareholders about the rights offering and the terms under which they can subscribe for new shares. The document is not an announcement of a report, nor is it a financial report like an annual or interim report. It is also not a proxy solicitation or voting results announcement. The content clearly relates to a capital raising activity through a rights offering, which fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the actual circular, not just a brief notice or announcement. Therefore, the correct classification is CAP with high confidence.
2023-06-13 English
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed notice regarding a rights offering (placement de droits) by Neural Therapeutics Inc., dated June 13, 2023. It includes information about the terms of the rights offering, eligibility, subscription price, expiration date, and use of proceeds. The text is focused on informing shareholders about the rights offering and the conditions under which they can subscribe to new shares. There is no indication that this is a full financial report, audit report, or earnings release. It is not a proxy solicitation or voting results announcement. The document is a formal offering notice related to capital raising through a rights issue, which fits the category of Capital/Financing Update (CAP). The length (15,000 characters) and detailed content confirm it is the actual notice, not just an announcement of a report. Therefore, the appropriate classification is CAP with high confidence.
2023-06-13 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification statement by the Chief Financial Officer regarding the interim financial report and interim MD&A for the period ended January 31, 2023. It is a FORM 52-109FV2 Venture Issuer Basic Certificate, which is a certification of interim filings. The document does not contain actual financial data or substantive financial analysis but rather attests to the accuracy and fair presentation of the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2950 characters), consistent with a certification rather than a full report.
2023-06-01 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.